Show simple item record

dc.contributor.authorAsher, Viren
dc.contributor.authorBali, Anish
dc.date.accessioned2016-10-25T15:20:47Z
dc.date.available2016-10-25T15:20:47Z
dc.date.issued2010-12
dc.identifier.citationWorld J Surg Oncol. 2010 Dec 29;8:113. doi: 10.1186/1477-7819-8-113.language
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/562
dc.description.abstractVoltage gated potassium channels have been extensively studied in relation to cancer. In this review, we will focus on the role of two potassium channels, Ether à-go-go (Eag), Human ether à-go-go related gene (HERG), in cancer and their potential therapeutic utility in the treatment of cancer. Eag and HERG are expressed in cancers of various organs and have been implicated in cell cycle progression and proliferation of cancer cells. Inhibition of these channels has been shown to reduce proliferation both in vitro and vivo studies identifying potassium channel modulators as putative inhibitors of tumour progression. Eag channels in view of their restricted expression in normal tissue may emerge as novel tumour biomarkers.language
dc.language.isoenlanguage
dc.subjectVoltage Gated Potassium Channelslanguage
dc.subjectCancerlanguage
dc.subjectHuman Ether à-go-go Related Genelanguage
dc.subjectEther à-go-golanguage
dc.titleEag and HERG potassium channels as novel therapeutic targets in cancer.language
dc.typeArticlelanguage


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record